v3.26.1
Segment Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Total Revenue $ 5,053,800 $ 4,797,100
Cost of revenues 3,750,700 2,790,500
Depreciation and Amortization 610,000 750,700
Assets 12,607,600 11,560,800
Benchtop Laboratory Equipment    
United States revenue 3,753,800 3,107,300
Foreign revenue 0 0
Total Revenue 3,753,800 3,107,300
Cost of revenues 2,677,500 2,076,700
Compensation and other personnel expenses 709,700 900,100
Other expenses 774,100 916,700
Depreciation and Amortization 45,600 85,000
Segment Loss From Operations (453,100) (871,100)
Assets 3,392,000 5,751,500
Long-Lived Asset Expenditures 16,300 75,900
Bioprocessing Systems    
United States revenue 424,400 563,900
Foreign revenue 875,600 1,125,900
Total Revenue 1,300,000 1,689,800
Cost of revenues 1,073,200 713,800
Compensation and other personnel expenses 3,964,300 3,899,000
Other expenses 1,785,800 2,219,800
Depreciation and Amortization 564,400 665,700
Segment Loss From Operations (6,087,700) (5,808,500)
Assets 3,510,600 3,824,300
Long-Lived Asset Expenditures 46,900 23,000
Corporate and Other    
United States revenue 0 0
Foreign revenue 0 0
Total Revenue   0
Cost of revenues 0 0
Compensation and other personnel expenses 388,000 418,700
Other expenses 961,000 1,118,000
Depreciation and Amortization 0 0
Segment Loss From Operations (1,349,000) (1,536,800)
Assets 5,705,000 1,985,000
Long-Lived Asset Expenditures 0 0
Consolidated    
United States revenue 4,178,200 3,671,200
Foreign revenue 875,600 1,125,900
Total Revenue 5,053,800 4,797,100
Cost of revenues 3,750,700 2,790,500
Compensation and other personnel expenses 5,062,100 5,217,800
Other expenses 3,520,900 4,254,500
Depreciation and Amortization 610,000 750,700
Segment Loss From Operations (7,889,900) (8,216,400)
Assets 12,607,600 11,560,800
Long-Lived Asset Expenditures $ 63,200 $ 98,900